Laura's questions to Recursion Pharmaceuticals Inc (RXRX) leadership • FY 2024
Question
Laura asked about the potential impact of changing NIH funding levels on Recursion's strategy and ability to discover medicines.
Answer
CEO Christopher Gibson stated there is no short-term impact on Recursion, though the company benefited from NIH grants in its early days. However, he expressed significant concern for the broader biotech ecosystem, particularly for startups and the long-term academic talent pipeline, if funding cuts persist. He noted his involvement in a fund to help support early-stage companies in their incubator to bridge this potential gap.